CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programs
Reuters2026/08/06 13:04- CG Oncology highlighted Phase 3 BOND-003 Cohort C in high-risk BCG-unresponsive CIS, reporting 76% complete response at any time.
- Durability metrics showed 46.4% complete response at 12 months, 41.8% at 24 months, with 90% of 12-month responders remaining in response.
- Safety update cited zero grade 3+ treatment-related adverse events or deaths, with most adverse events grade 1-2.
- Phase 3 BOND-003 Cohort P in high-risk BCG-unresponsive Ta/T1 reported high-grade event-free survival of 95.7% at 3 months, 84.6% at 6 months.
- Manufacturing readiness noted current capacity of 40,000-50,000 vials per year, with a 10x scale-up process underway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ahead of the UK interest rate decision, the central bank governor downplays inflation threat: secondary effects remain "relatively moderate".
With the Bank of England's interest rate decision approaching on September 17, Governor Bailey stated at the Jackson Hole Symposium that the labor market remains persistently weak and that second-round inflation effects are moderate, saying, "We can continue to observe this situation." At the symposium, MPC member Mann, who supported a rate hike in July, warned that the spillover effects from the US and the rising dominance of the US dollar pose potential shocks to the transmission of the UK's monetary policy. The market has already priced in a 25 basis point rate hike by the UK this year, with bets on another hike next spring.
Power Metallic modifies Red Cloud market-stabilization fees to monthly prepayment
Asana CEO Daniel Mark Rogers disposes of 1,655 common shares worth $16,550
HMOBI Participações calls extraordinary shareholders meeting
Crypto prices
More
